
Dymista® is suitable for long-term use
For perennial allergic rhinitis patients to get the full therapeutic benefit, regular use of treatment is essential. With Dymista®, the duration of treatment should correspond to the period of allergenic exposure and Dymista® is suitable for long-term use'
A 52-week open-label study showed Dymista® has a large therapeutic spectrum, covering not only seasonal allergic rhinitis but also perennial allergic rhinitis with consistent superiority over an intranasal certicostemid2
Fluticasone propionate when delivered in a nasal spray exerts a topical effect without systemic effects due to low systemic bioavailabitlity3
Systemic absorption is negligible with mometasone furoate, fluticasone furcate and fluticasone propionate. Systemic absorption is modest for the remainder, and high for betamethasone which should be used short-term only.

FIGURE: Bioavailability of intranasal corticosteroids. The more recent molecules have little systemic uptake and are suitable for long-term therapy. Adapted from Scudding et al. 20173
Further Your Understanding
Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.
-
Allergic Rhinitis
-
Impact of Rhinitis
-
Onset
-
Treatment
-
Guidelines
-
Clinical Papers
References
- Dymista, Summary of Product Characteristics
- Price D et al. A New Therapy (MP29-02) Is Effective for the Long-Term Treatment, Chronic Rhinilis. J Investig Allergol Clin Immunol 2013 Vol. 23(7): 495-503.
- Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; Frist edition 2007). Clin Exp Allergy. 2017; 47:856-889
Want to expand your knowledge…
Register to ViatrisConnect and subscribe to our Allergy newsletters to continue reading.
Viatris Connect is an online platform for healthcare professionals. Register today and enjoy this article and a selection of others for free.
REGISTER NOW